<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393597</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1458102</org_study_id>
    <nct_id>NCT04393597</nct_id>
  </id_info>
  <brief_title>Effects of Food on the Pharmacokinetics of DWJ1458 in Healthy Adults</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics of Orally Administered DWJ1458 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the food effect on the pharmacokinetics of DWJ1458
      after oral administration in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the food effect on the pharmacokinetics of DWJ1458
      after oral administration in healthy volunteers: Randomized, open-label, oral, single-dose,
      crossover study
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We decided to discontinue this particular clinical study through internal discussion.
  </why_stopped>
  <start_date type="Anticipated">May 28, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: AUC0-t</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: Cmax</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Maximum plasma drug concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: AUCinf</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from drug administration to drug elimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: Tmax</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Time to reach maximum plasma concentration following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: t1/2</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: Vd/F</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Apparent volume of distribution after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of DWJ1458: Cl/F</measure>
    <time_frame>0 - 144 hours after dosing</time_frame>
    <description>Apparent total clearance of drug from plasma after oral administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1458 (fasted)</intervention_name>
    <description>Subjects take single dose of DWJ1458 on a fated condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1458 (fed)</intervention_name>
    <description>Subjects take single dose of DWJ1458 after high-fat diet</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 to 55 years

          -  BMI 18.5≥ and ≤27.0 kg/m²

          -  Female subjects must be menopause or surgically infertility.

          -  Male subjects must consent to contraception for at least 60 days after the study
             period and the final administration of the study drug.

          -  Those who understand the requirements of the study and sign a written informed
             consent, and also accept all the restrictions imposed during the course of the study.

        Exclusion Criteria:

          -  History of hypersensitivity to investigational product

          -  Participation in a clinical drug study or bioequivalence study 6 months prior to the
             present study

          -  The subject who is judged to be unsuitable as a test subject in a screening test.

          -  The subject who is judged to be unsuitable for participation in a clinical trial due
             to other reasons determined by the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

